Scopus BioPharma Inc. (SCPS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 392.26 Thousand USD | -95.21% |
| 2021 | 8.18 Million USD | 314.76% |
| 2020 | 1.97 Million USD | 155.81% |
| 2019 | 771.68 Thousand USD | 481.8% |
| 2018 | 132.63 Thousand USD | -37.69% |
| 2017 | 212.87 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 497.55 Thousand USD | -68.97% |
| 2023 Q1 | 1.6 Million USD | 308.74% |
| 2022 Q2 | 1.67 Million USD | -63.69% |
| 2022 FY | 392.26 Thousand USD | -95.21% |
| 2022 Q3 | 415.67 Thousand USD | -75.15% |
| 2022 Q4 | 392.26 Thousand USD | -5.63% |
| 2022 Q1 | 4.6 Million USD | -43.72% |
| 2021 Q3 | 4.03 Million USD | -40.78% |
| 2021 FY | 8.18 Million USD | 314.76% |
| 2021 Q2 | 6.8 Million USD | -21.08% |
| 2021 Q1 | 8.62 Million USD | 337.01% |
| 2021 Q4 | 8.18 Million USD | 103.09% |
| 2020 FY | 1.97 Million USD | 155.81% |
| 2020 Q4 | 1.97 Million USD | 59.23% |
| 2020 Q3 | 1.23 Million USD | 0.0% |
| 2019 Q4 | 771.68 Thousand USD | 0.0% |
| 2019 FY | 771.68 Thousand USD | 481.8% |
| 2019 Q1 | 1 Million USD | 0.0% |
| 2019 Q2 | 1.47 Million USD | 47.14% |
| 2018 FY | 132.63 Thousand USD | -37.69% |
| 2017 FY | 212.87 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -31.136% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 93.161% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 97.331% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 98.743% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 87.818% |
| Better Therapeutics, Inc. | 22.94 Million USD | 98.29% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 98.632% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 89.475% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 98.091% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 98.143% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 99.391% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | 83.334% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 99.447% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 98.499% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -416.186% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 96.777% |
| Molecular Templates, Inc. | 35.38 Million USD | 98.891% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | 91.027% |
| NexImmune, Inc. | 8.59 Million USD | 95.436% |
| Orgenesis Inc. | 14.55 Million USD | 97.304% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 96.676% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -214.711% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 93.094% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.917% |
| Statera Biopharma, Inc. | 21.16 Million USD | 98.147% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 96.118% |
| Trevena, Inc. | 40.6 Million USD | 99.034% |
| Vaxxinity, Inc. | 44.35 Million USD | 99.116% |
| Vaccinex, Inc. | 3.63 Million USD | 89.197% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -889.169% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 99.308% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | 29.413% |